Research programme: bivalent COVID-19 vaccines - Icosavax
Latest Information Update: 03 May 2024
At a glance
- Originator Icosavax
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections